The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Current treatment options for hemophilia A
Wolfgang Miesbach, MD, PhD, University Hospital Frankfurt, Frankfurt, Germany, summarises the current treatment options for hemophilia A. A recent paper by the European Association for Haemophilia and Allied Disorders (EAHAD) and the European Haemophilia Consortium (EHC) proposes that gene therapy treatment in Europe be carried out using a ‘hub-and-spoke’ model of hemophilia comprehensive care centers (national hubs) and hemophilia treatment centers (spokes). It is hoped that communication and cooperation between these centers will lead to the same success and safety for gene therapy as has been seen in clinical trials. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Wolfgang Miesbach, MD, PhD, discloses links to Bayer, Biomarin, Biotest, CSL Behring, Chugai, Freeline, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Takeda/Shire, uniQure.
